H3 receptor antagonist for use in the treatment of alzheimer's disease
AssigneeSanofi
InventorsPascal BARNEOUD, Veronique BLANCHARD-BREGEON, Veronique MARY, Jean MENAGER, Philippe DELAY-GOYET, Mathilde LOPEZ-GRANCHA, Thomas ROONEY, Nathalie SCHUSSLER
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
Claims20
A method of preventing or delaying the disease progression of a tauopathy or related neurodegenerative disease, comprising administering to a patient in need thereof 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.